This article is intended for general educational purposes only and does not constitute medical advice. Anyone with concerns about tuberculosis symptoms, exposure, or treatment should consult a qualified healthcare provider or their local health authority.
Tuberculosis — a bacterial infection caused by Mycobacterium tuberculosis primarily affecting the lungs but capable of affecting virtually any organ — remains one of the most significant infectious disease burdens globally, with a disproportionate share of the global caseload concentrated in African countries. Despite being a curable disease with effective treatments available for decades, tuberculosis continues to cause substantial preventable mortality across the continent, reflecting the intersection of high transmission risk, health system access barriers, the amplifying effect of HIV coinfection, and the growing challenge of drug-resistant tuberculosis strains.
The Scale of Tuberculosis in Africa
Sub-Saharan Africa carries a disproportionate share of the global tuberculosis burden, with high incidence rates in many countries and southern Africa in particular facing some of the highest tuberculosis rates in the world. The strong geographic overlap between HIV and tuberculosis is a central driver of this burden: HIV infection substantially weakens the immune system, dramatically increasing the likelihood that exposure to tuberculosis bacteria will progress to active disease and that active disease will be more severe. People living with HIV are significantly more likely to develop active tuberculosis than HIV-negative individuals with equivalent exposure, and tuberculosis is a leading cause of death among people living with HIV in high-burden African settings. The two epidemics are deeply intertwined, and addressing tuberculosis effectively in high-HIV-prevalence settings requires integration of tuberculosis and HIV services rather than treating them as separate programmatic concerns.
Transmission and Risk Factors
Tuberculosis is transmitted through the air when a person with active pulmonary tuberculosis coughs, sneezes, or speaks, releasing bacteria-containing droplets that can be inhaled by others in the same enclosed space. Risk of transmission is greatest with prolonged, close contact with an infectious person in poorly ventilated environments. Risk factors for progression from latent infection — where bacteria are present but the immune system prevents active disease — to active tuberculosis include HIV infection, malnutrition, diabetes, tobacco smoking, heavy alcohol use, and other conditions or treatments that compromise immune function. The social and economic conditions associated with poverty — crowded living conditions, inadequate nutrition, limited healthcare access — create overlapping risk environments that contribute to the geographic and socioeconomic patterning of tuberculosis burden.
Diagnosis
Accurate and timely diagnosis is foundational to tuberculosis control: patients who are not diagnosed cannot begin treatment, continue to be infectious, and are at risk of disease progression. Traditional tuberculosis diagnosis using sputum smear microscopy is relatively simple but has limited sensitivity — missing a significant proportion of cases, particularly in people with HIV coinfection who often have paucibacillary disease. Molecular diagnostic tests offering faster results and substantially improved sensitivity have been introduced at scale across many African settings over the past decade, improving diagnosis rates particularly for HIV-associated tuberculosis. Chest X-ray interpretation, manual and increasingly AI-assisted, supports tuberculosis screening particularly in high-risk groups. A significant proportion of tuberculosis cases continue to be missed or diagnosed late, either because people do not present for care — due to stigma, access barriers, or limited symptom recognition — or because diagnostic capacity at facility level is insufficient to identify all cases that do present.
Treatment and the Standard Regimen
Drug-sensitive tuberculosis is curable with a standard treatment regimen involving a combination of antibiotics taken over several months. Completing the full course of treatment is essential both for achieving cure and for preventing the emergence of drug resistance — incomplete treatment allows partially resistant bacteria to survive and multiply. Treatment support interventions — including directly observed therapy where a healthcare worker or designated supporter observes each dose being taken, patient education and counseling, and addressing practical barriers to adherence such as travel costs to health facilities — are important components of tuberculosis treatment programs aimed at ensuring treatment completion. Integration of tuberculosis treatment services with HIV care for coinfected patients, including concurrent antiretroviral therapy and preventive therapy against opportunistic infections, is standard practice in most high-burden African settings.
Drug-Resistant Tuberculosis
Drug-resistant tuberculosis — strains resistant to one or more of the first-line antibiotics used in standard treatment — presents a significantly more serious clinical and public health challenge than drug-sensitive disease. Multidrug-resistant tuberculosis, resistant to the two most important first-line drugs, requires treatment with second-line medications that are more expensive, more toxic, and must be taken for longer periods, resulting in lower treatment success rates and higher costs for both patients and health systems. Extensively drug-resistant tuberculosis, with additional resistance to key second-line drugs, is even more difficult to treat. The emergence and spread of drug-resistant tuberculosis reflects both the historical inadequacy of tuberculosis treatment programs — which allowed incomplete or inadequate treatment to drive resistance — and the ongoing challenge of ensuring high treatment completion rates to prevent further resistance development. Southern Africa has been particularly affected by drug-resistant tuberculosis, requiring dedicated programmatic and clinical infrastructure for its management.
Preventive Therapy
Tuberculosis preventive therapy — treating people with latent tuberculosis infection before they develop active disease — is an important component of comprehensive tuberculosis control, particularly for people at elevated risk of progression, including people living with HIV and household contacts of people with active tuberculosis. Simplified shorter regimens for preventive therapy have been developed and are increasingly being implemented in high-burden settings, alongside expanded screening approaches to identify people who would benefit from preventive therapy. Scaled-up preventive therapy is expected to contribute meaningfully to reductions in tuberculosis incidence over time, particularly in high-risk groups.
Vaccine Research
The BCG vaccine, used routinely in childhood immunization programs across most African countries, provides protection against severe forms of tuberculosis disease in young children but has variable and generally limited effectiveness against pulmonary tuberculosis in adults, which is the primary driver of ongoing transmission. Development of new, more effective tuberculosis vaccines that protect against adult pulmonary disease is a longstanding research priority, and several vaccine candidates are in various stages of clinical evaluation. A safe and effective tuberculosis vaccine would be transformative for control of the disease globally and particularly in high-burden African settings where other interventions alone have been insufficient to achieve the reductions in incidence needed to end the epidemic.
Looking Ahead
Achieving meaningful reductions in the tuberculosis burden across Africa requires sustained progress on multiple simultaneous fronts: expanding access to rapid, sensitive diagnosis; ensuring treatment completion through support interventions and patient-centered care; scaling up preventive therapy for high-risk groups; managing drug-resistant tuberculosis with improved diagnostic and treatment tools; and integrating tuberculosis services fully with HIV programs in high-coprevalence settings. Progress is being made, and the tools for tuberculosis control are substantially better than they were a generation ago. Closing the remaining gap between what is technically achievable and what is actually delivered in high-burden settings is a challenge of health system capacity, political commitment, and sustained financing as much as a challenge of scientific discovery. Individuals with any concerns about tuberculosis symptoms or exposure should consult a qualified healthcare provider.
